Our Mission & Values Our Leadership Team Our History Corporate Social Responsibility Astex Pharmaceuticals is led by a globally experienced management team with knowledge and expertise in drug discovery, development and commercialization. UK – Discovery Research USA – Product Development Martin Buckland Harold N. Keer Nipun Davar Talat Ashraf D. Jeffery Grimes Joseph Iovino Samuel Jason Aram Oganesian Pratibha Sampeur Sonia Souza Nancy Worrell California, USA Astex Pharmaceuticals, Inc. Martin Buckland President and Chief Corporate Officer Harold N. Keer Chief Medical Officer Nipun Davar Senior Vice President, Product Development Talat Ashraf Vice President, Vice President, Clinical Safety and Risk Management D. Jeffery Grimes Vice President, Corporate Counsel & Compliance Officer Joseph Iovino Vice President, Quality Assurance & Compliance Samuel Jason Vice President, Finance Aram Oganesian Vice President, Clinical Pharmacology & Non-Clinical Development Pratibha Sampeur Vice President, Clinical Operations Sonia Souza Vice President, Biostatistics & Data Management Nancy Worrell Vice President, Human Resources © Astex Pharmaceuticals All rights reserved Useful links Home Sitemap Privacy Policy Terms of Use Legal Member of the Otsuka Group We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok

Discover Astex Our Mission & Values Our Leadership Team UK – Discovery Research Jeremy Carmichael Harren Jhoti Michelle Jones Neil Jones John Lyons Chris Murray David Rees Nicola Wallis Nicola Wilsher USA – Product Development Mohammad Azab Martin Buckland Harold N. Keer Nipun Davar Yong Hao Joseph Iovino Samuel Jason Nancy Worrell Patti Oto Our History Corporate Social Responsibility R&D Clinical Pipeline Proprietary Products and Programs Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors) ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors) Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies) ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas) Partnered Products and Programs Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology) Balversa® (erdafitinib) FGFr inhibitor (Oncology) AZD5363 PKB/Akt Inhibitor (Oncology) Multiple Targets and Therapeutic Areas Pyramid™ Discovery Platform Oncology and CNS Discovery Sustaining Innovation Partnering Our People & Culture Career Opportunities Media Press Releases Conferences & Meetings Presentations & Publications Interactive Scientific Resources Interactive Software Astex in the News Contact © Astex Pharmaceuticals All rights reserved Useful links Home Sitemap Privacy Policy Terms of Use Legal Member of the Otsuka Group We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok